PharmaBlock Sciences (Nanjing), Inc. (SZSE:300725) is a leading provider of innovative chemistry products & services throughout the pharmaceutical R&D process and commercial production. Its core businesses include: a rationally designed building blocks (BBs) collection, supplying from discovery, to development & commercial; development & manufacturing of RSMs, intermediates & APIs for drug development & commercial. Officially operated in 2008, PharmaBlock has rapidly gained recognition for its outstanding capabilities in the design, synthesis, & supply of novel BBs. It has generated a large and unique collection of high-quality and diverse BBs, which are increasingly adopted by drug hunters to enrich the structure options, improve compound quality, expand patent space and eventually accelerate drug discovery projects. Inspired by the BBs, it has established a powerful drug discovery platform for medicinal chemists to quickly identify hit/lead. The platform includes a set of efficient tools, including but not limited to FBDD, DELT, & Virtual Screening. Following the new molecules advancing from discovery to development, and into the market, the company is committed to a more comprehensive & long-term service to valued customers. In addition to strengthening process R&D capabilities & mfg. capacity to secure the sustainable supply of BBs, the company is providing CDMO solutions of RSMs, key intermediates & APIs. To further realize safe, efficient and green process & mfg., it has developed an advanced chemistry & engineering technology platform, featuring flow chemistry, micropacked bed hydrogenation, catalysis, crystallization, solid state chemistry etc. Over the past years, PharmaBlock has partnered with almost all the top pharmaceutical companies, and hundreds of small to medium-sized biotechs around the world. Our ever changing mission is to support clients to accelerate drug discovery & development, and move the new molecule to commercial in full speed.